POSIACT

Description

COMPOSITION: Each ml contains :
Etoposide IP 20 mg
Dehydrated Alcohol IP 30.5% v/v
Benzyl Alcohol IP 30 mg
Sterile non aqueous base q.s.
POSIACT

INDICATIONS AND USAGE : Etoposide Injection is indicated in
the management of the following neoplasms: Refractory Testicular
Tumors: Etoposide Injection in combination therapy with other
approved chemotherapeutic agents in patients with refractory
testicular tumors who have already received appropriate surgical,
chemotherapeutic, and radiotherapeutic therapy. Small Cell Lung
Cancer: Etoposide Injection and/or capsules in combination with
other approved chemotherapeutic agents as first line treatment in
patients with small cell lung cancer.

PACKING: 1 Vial Injection